Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 2

Status

Completed 5Unknown 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

CNS 4Other solid neoplasm 1Dermatologic 1

Conditions

Glioblastoma 3Brain Neoplasms 3Recurrence 2Neoplasm Metastasis 2Refractory Solid Tumors 1Melanoma 1

Interventions

Cisplatin 3202Cyclophosphamide 3195Carboplatin 2977Radiotherapy 2790Paclitaxel 2718Gemcitabine 2572pembrolizumab 2385Bevacizumab 2209Docetaxel 2199Fluorouracil 1851Capecitabine 1833Oxaliplatin 1742Dexamethasone 1605Nivolumab 1581Doxorubicin 1501Rituximab 1488Magnetic Resonance Spectroscopy 1387Etoposide 1346Irinotecan 1248Leucovorin 1226Drug Therapy 1205Cytarabine 1130Pemetrexed 1076fludarabine 1063Specimen Handling 1017Vincristine 964Cetuximab 945Trastuzumab 945Prednisone 942Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
verubulin × Clear all
NCT01285414 2012-04-11

Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme

Myrexis Inc.

Phase 2 Completed
5 enrolled
CNS

Brain Neoplasms, Glioblastoma

NCT00892931 2011-10-14

Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme

Myrexis Inc.

Phase 2 Completed
56 enrolled
CNS

Brain Neoplasms, Glioblastoma, Recurrence

NCT00635557 2011-03-25

Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme

Myrexis Inc.

Phase 1/2 Unknown
30 enrolled
CNS

Glioblastoma, Recurrence

NCT00609011 2010-08-23

Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma

Myrexis Inc.

Phase 1/2 Completed
22 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

NCT00393965 2008-02-13

Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases

Myrexis Inc.

Phase 1 Completed
18 enrolled
CNS

Brain Neoplasms, Neoplasm Metastasis

NCT00394446 2008-02-13

Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors

Myrexis Inc.

Phase 1 Completed
48 enrolled
Other solid neoplasm

Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡